Back to top
more

OptiNose (OPTN)

(Delayed Data from NSDQ)

$0.93 USD

0.93
571,324

-0.04 (-4.38%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.93 0.00 (0.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 10% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?

OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

5 Top-Ranked Stocks With Rising P/E for Solid Returns

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).

OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 118.18% and 14.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of -12.90% and 21.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?

Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aveanna Healthcare (AVAH) Reports Q3 Loss, Misses Revenue Estimates

Aveanna (AVAH) delivered earnings and revenue surprises of -175% and 1.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 4.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America

Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America

Sanghamitra Saha headshot

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

OptiNose (OPTN) Sees Hammer Chart Pattern: Time to Buy?

OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.